172 related articles for article (PubMed ID: 8944568)
21. Are screening and surveillance for Barrett's oesophagus really worthwhile?
Sharma P; Sidorenko EI
Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i27-32. PubMed ID: 15711005
[TBL] [Abstract][Full Text] [Related]
22. The Veneto Region's Barrett's Oesophagus Registry: aims, methods, preliminary results.
Zaninotto G; Minnei F; Guirroli E; Ceolin M; Battaglia G; Bellumat A; Betetto G; Bozzola L; Cassaro M; Cataudella G; Dal Bò N; Farinati F; Florea G; Furlanetto A; Galliani E; Germanà B; Guerini A; Macrì E; Marcon V; Mastropaolo G; Meggio A; Miori G; Morelli L; Murer B; Norberto L; Togni R; Valiante F; Rugge M
Dig Liver Dis; 2007 Jan; 39(1):18-25. PubMed ID: 17141593
[TBL] [Abstract][Full Text] [Related]
23. Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis.
Gupta N; Bansal A; Wani SB; Gaddam S; Rastogi A; Sharma P
Gastrointest Endosc; 2011 Sep; 74(3):610-624.e2. PubMed ID: 21741639
[TBL] [Abstract][Full Text] [Related]
24. Prevention of the neoplastic progression of Barrett's oesophagus by endoscopic argon beam plasma ablation.
Morris CD; Byrne JP; Armstrong GR; Attwood SE
Br J Surg; 2001 Oct; 88(10):1357-62. PubMed ID: 11578292
[TBL] [Abstract][Full Text] [Related]
25. Barrett's oesophagus: results from a 13-year surveillance programme.
Bani-Hani K; Sue-Ling H; Johnston D; Axon AT; Martin IG
Eur J Gastroenterol Hepatol; 2000 Jun; 12(6):649-54. PubMed ID: 10912484
[TBL] [Abstract][Full Text] [Related]
26. Screening and Surveillance for Barrett's Esophagus: Is It Cost-Effective?
Inadomi JM; Saxena N
Dig Dis Sci; 2018 Aug; 63(8):2094-2104. PubMed ID: 29948571
[TBL] [Abstract][Full Text] [Related]
27. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma.
van Sandick JW; van Lanschot JJ; Kuiken BW; Tytgat GN; Offerhaus GJ; Obertop H
Gut; 1998 Aug; 43(2):216-22. PubMed ID: 10189847
[TBL] [Abstract][Full Text] [Related]
28. [Impact of endoscopic surveillance of Barrett's esophagus on survival of patients with esophageal adenocarcinoma].
Incarbone R; Bonavina L; Bassi F; Peracchia A
Chir Ital; 2002; 54(5):591-6. PubMed ID: 12469454
[TBL] [Abstract][Full Text] [Related]
29. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus.
Katz D; Rothstein R; Schned A; Dunn J; Seaver K; Antonioli D
Am J Gastroenterol; 1998 Apr; 93(4):536-41. PubMed ID: 9576444
[TBL] [Abstract][Full Text] [Related]
30. Should patients with GERD be screened once at least for Barrett's epithelium? Con: Patients with GERD should be screened once at least for Barrett's esophagus--medicine or magic?
Moayyedi P
Am J Gastroenterol; 2004 Dec; 99(12):2293-5. PubMed ID: 15571570
[No Abstract] [Full Text] [Related]
31. New developments in the endoscopic surveillance of Barrett's oesophagus.
Bergman JJ; Tytgat GN
Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i38-42. PubMed ID: 15711007
[TBL] [Abstract][Full Text] [Related]
32. Barrett's oesophagus: a review of costs of the illness.
Arguedas MR; Eloubeidi MA
Pharmacoeconomics; 2001; 19(10):1003-11. PubMed ID: 11735670
[TBL] [Abstract][Full Text] [Related]
33. How to get the most out of costly Barrett's oesophagus surveillance.
Braden B; Jones-Morris E
Dig Liver Dis; 2018 Sep; 50(9):871-877. PubMed ID: 29730158
[TBL] [Abstract][Full Text] [Related]
34. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial.
Heath EI; Canto MI; Piantadosi S; Montgomery E; Weinstein WM; Herman JG; Dannenberg AJ; Yang VW; Shar AO; Hawk E; Forastiere AA;
J Natl Cancer Inst; 2007 Apr; 99(7):545-57. PubMed ID: 17405999
[TBL] [Abstract][Full Text] [Related]
35. Miniprobe confocal laser microscopy for the detection of invisible neoplasia in patients with Barrett's oesophagus.
Pohl H; Rösch T; Vieth M; Koch M; Becker V; Anders M; Khalifa AC; Meining A
Gut; 2008 Dec; 57(12):1648-53. PubMed ID: 18755886
[TBL] [Abstract][Full Text] [Related]
36. Endoscopic submucosal dissection plus radiofrequency ablation of neoplastic Barrett's esophagus.
Neuhaus H; Terheggen G; Rutz EM; Vieth M; Schumacher B
Endoscopy; 2012 Dec; 44(12):1105-13. PubMed ID: 22968641
[TBL] [Abstract][Full Text] [Related]
37. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
38. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.
Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ;
Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200
[TBL] [Abstract][Full Text] [Related]
39. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study.
Conio M; Blanchi S; Lapertosa G; Ferraris R; Sablich R; Marchi S; D'Onofrio V; Lacchin T; Iaquinto G; Missale G; Ravelli P; Cestari R; Benedetti G; Macrì G; Fiocca R; Munizzi F; Filiberti R
Am J Gastroenterol; 2003 Sep; 98(9):1931-9. PubMed ID: 14499768
[TBL] [Abstract][Full Text] [Related]
40. Surveillance and screening of Barrett's oesophagus.
Lao-Sirieix P; Fitzgerald R
Br J Hosp Med (Lond); 2006 Jul; 67(7):355-9. PubMed ID: 16884144
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
